Literature DB >> 17192057

When does MMR loss occur during HNPCC progression?

Darryl Shibata1.   

Abstract

Inactivation of DNA mismatch repair (MMR) is the hallmark of hereditary nonpolyposis colorectal cancer (HNPCC) and sporadic colorectal cancers with microsatellite instability (MSI+). MMR loss results in a markedly elevated mutation rate, and many MS mutations are found in MSI+ cancers. In theory, it is possible to estimate the interval between MMR loss and cancer removal by counting numbers of cancer MS mutations--the more MS mutations, the longer the intervals since MMR loss. Using this somatic molecular clock approach, MMR loss is estimated to precede transformation (clonal expansion) and likely occurs in normal appearing colon. Surprising, ages at MMR loss are more consistent with MMR loss as a relatively late event during progression to MSI+ cancer.

Entities:  

Mesh:

Year:  2006        PMID: 17192057     DOI: 10.3233/cbm-2006-21-204

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  7 in total

Review 1.  Familial/inherited cancer syndrome: a focus on the highly consanguineous Arab population.

Authors:  Fawz S AlHarthi; Alya Qari; Alaa Edress; Malak Abedalthagafi
Journal:  NPJ Genom Med       Date:  2020-02-03       Impact factor: 8.617

2.  Development of sporadic microsatellite instability in colorectal tumors involves hypermethylation at methylated-in-tumor loci in adenoma.

Authors:  Michiel F G de Maat; Norihiko Narita; Anne Benard; Tetsunori Yoshimura; Christine Kuo; Rob A E M Tollenaar; Noel F C C de Miranda; Roderick R Turner; Cornelis J H van de Velde; Hans Morreau; Dave S B Hoon
Journal:  Am J Pathol       Date:  2010-10-15       Impact factor: 4.307

Review 3.  The quiescent cellular state is Arf/p53-dependent and associated with H2AX downregulation and genome stability.

Authors:  Ken-Ichi Yoshioka; Yuko Atsumi; Hirokazu Fukuda; Mitsuko Masutani; Hirobumi Teraoka
Journal:  Int J Mol Sci       Date:  2012-05-24       Impact factor: 6.208

4.  Mismatch repair-deficient crypt foci in Lynch syndrome--molecular alterations and association with clinical parameters.

Authors:  Laura Staffa; Fabian Echterdiek; Nina Nelius; Axel Benner; Wiebke Werft; Bernd Lahrmann; Niels Grabe; Martin Schneider; Mirjam Tariverdian; Magnus von Knebel Doeberitz; Hendrik Bläker; Matthias Kloor
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

5.  A novel panel of short mononucleotide repeats linked to informative polymorphisms enabling effective high volume low cost discrimination between mismatch repair deficient and proficient tumours.

Authors:  Lisa Redford; Ghanim Alhilal; Stephanie Needham; Ottie O'Brien; Julie Coaker; John Tyson; Leonardo Maldaner Amorim; Iona Middleton; Osagi Izuogu; Mark Arends; Anca Oniscu; Ángel Miguel Alonso; Sira Moreno Laguna; Richard Gallon; Harsh Sheth; Mauro Santibanez-Koref; Michael S Jackson; John Burn
Journal:  PLoS One       Date:  2018-08-29       Impact factor: 3.240

Review 6.  Familial/inherited cancer syndrome: a focus on the highly consanguineous Arab population.

Authors:  Fawz S AlHarthi; Alya Qari; Alaa Edress; Malak Abedalthagafi
Journal:  NPJ Genom Med       Date:  2020-02-03       Impact factor: 8.617

7.  Intra-tumor heterogeneity of MLH1 promoter methylation revealed by deep single molecule bisulfite sequencing.

Authors:  Katherine E Varley; David G Mutch; Tina B Edmonston; Paul J Goodfellow; Robi D Mitra
Journal:  Nucleic Acids Res       Date:  2009-06-03       Impact factor: 16.971

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.